When was OptiBiotix Health founded?

OptiBiotix Health was founded in 2012 and raised its 1st funding round 4 years after it was founded.

Where is OptiBiotix Health located?

OptiBiotix Health is headquartered in York, United Kingdom.

Who is the current CEO of OptiBiotix Health?

Stephen Ohara of OptiBiotix Health.

How many employees does OptiBiotix Health have?

As of Dec 31, 2021, the latest employee count at OptiBiotix Health is 12.

Is OptiBiotix Health a funded company?

OptiBiotix Health is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 05, 2016.

When was the latest funding round of OptiBiotix Health?

OptiBiotix Health's latest funding was a $***** Post IPO round on May 23, 2025, with participation from 0 investor. Its primary sector is Genomics. In United Kingdom, the Genomics sector has seen $66.7M in funding in 2026 to date.

Where does OptiBiotix Health rank among its competitors?

OptiBiotix Health ranks 15th amongst 282 active competitors, of which 61 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sernova, which secured $345K in Oct, 2025.

Who are the top competitors of OptiBiotix Health?

OptiBiotix Health's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Among them, Sernova secured the most recent funding round in October, 2025.

OptiBiotix Health - 2026 Company Profile, Team, Funding, Competitors & Financials

OptiBiotix Health is a public company based in York (United Kingdom), founded in 2012. It operates as a Developer of microbial strains for the treatment of human metabolic diseases. OptiBiotix Health has raised an undisclosed amount in funding. The company has 282 active competitors, including 61 funded and 58 that have exited. Its top competitors include companies like Rhythm Pharmaceuticals, MannKind Corp and Corcept.

Company Details

Developer of microbial strains for the treatment of human metabolic diseases. The company's proprietary platform technologies include OptiScreen and OptiBiotic designed to identify metabolic pathways and compounds that impact human physiology and bring potential health benefits. It can be used as food ingredients, supplements, or active compounds for the prevention and management of human metabolic diseases such as obesity, cholesterol and lipid distribution, and diabetes.

Website: optibiotix.com
Social

Key Metrics

Founded Year

2012

Location

York, United Kingdom

Stage

Public

Latest Funding Round

Post IPO, May 23, 2025, $*****

Investors

Seneca EIS Portfolio Fund & 3 more

Ranked

15^th among 282 active competitors

Employee Count

12 as on Dec 31, 2021

Similar Companies

Rhythm Pharmaceuticals & 322 more

Exit Details

Public

View OptiBiotix Health's full profile

OptiBiotix Health is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
OPTIBIOTIX HEALTH PLC CIN: 5880755 , Germany, Active	Jul 18, 2006	-	12 (As on Dec 31, 2021)

OptiBiotix Health got listed on Aug 05, 2014.

Click here to take a look at OptiBiotix Health's IPO in detail

OptiBiotix Health has raised funding over 4 rounds. Its first funding round was on Feb 05, 2016. OptiBiotix Health has 4 institutional investors.

Here is the list of recent funding rounds of OptiBiotix Health:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 23, 2025	9195230	Post IPO	6011938	9997324	7310498	1306201
May 30, 2018	8181415	Post IPO	8316761	2647911	5081638	7716481
Jan 30, 2018	3692375	Post IPO	2606652	8977833	1991256	3821358

Access funding benchmarks and valuations. Sign up today!

View details of OptiBiotix Health's funding rounds and investors

OptiBiotix Health's employee count trend

OptiBiotix Health has 12 employees as of Dec 21. The total employee count is 50.0% more than what it was in Dec 20. Here is OptiBiotix Health's employee count trend over the years:

Employee count trend for OptiBiotix Health

Uncover OptiBiotix Health's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OptiBiotix Health include Rhythm Pharmaceuticals, MannKind Corp and Corcept. Here is the list of Top 10 competitors of OptiBiotix Health, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	70/100
3rd	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, Longitude Capital & 7 others	68/100
4th	Pendulum 2012, San Francisco (United States), Series C	Manufacturer of medical probiotics	$111M	Meritech, Fonterra & 13 others	66/100
5th	MaaT Pharma 2014, Lyon (France), Public	Developer of microbiome therapy for the treatment of intestinal dysbiosis diseases	$42.3M	Bpifrance, Symbiosis & 11 others	65/100
6th	89bio 2018, San Francisco (United States), Acquired	Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders	$60M	Longitude Capital, Orbimed & 3 others	64/100
7th	Sernova 1998, London (Canada), Public	Regenerative medicine to deliver proteins and hormones for disease treatment	-	Evotec, National Research Council Canada & 1 others	61/100
8th	Kallyope 2014, New York City (United States), Series D	Discovering novel therapeutics for neurological and metabolic diseases	$479M	The Column Group, Illumina Ventures & 21 others	59/100
9th	Genfit 1999, Loos (France), Public	Therapeutics for cardiometabolic and neurodegenerative diseases.	-	Eiffel Investment Group, Ridgeback Capital Management ... & 2 others	59/100
10th	Finch Therapeutics 2004, Somerville (United States), Public	Developer of microbiome-based therapies by using human-first discovery platform	$184M	Willett Advisors, Avenir Growth Capital & 19 others	57/100
15th	OptiBiotix Health 2012, York (United Kingdom), Public	Developer of microbial strains for the treatment of human metabolic diseases	-	Seneca EIS Portfolio Fund, Enterprise Ventures ... & 2 others	55/100